Keros Therapeutics, Inc. (KROS)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 18.2M | 14.3M | 385K | 367K |
| Operating Income | -39.8M | -15.4M | -29.3M | -25.9M |
| Net Income | -30.7M | -7.3M | -23.5M | -23.7M |
| Diluted EPS | $-0.76 | $-0.18 | $-0.86 | $-1.21 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 151K | 3.5M | 244.1M |
| Operating Income | -107.7M | -167.5M | -209.6M | 67.6M |
| Net Income | -104.7M | -153.0M | -187.4M | 87.0M |
| Diluted EPS | $-4.15 | $-5.20 | $-5.00 | $2.30 |